BioSpace News Archive

FBSciences, which was recently acquired by Valent BioSciences, announces recent trial results further validating the power of their FBS Defense® technology and biopesticide line of leading crop protection solutions, showing superior or equivalent performance to the industry standard but with softer chemistries, improved plant health and crop quality outcomes, and better sustainability for the environment.

Pharma-Bio Serv, Inc. announced that it has retained ACP Capital Markets LLC for investment banking and M&A advisory services.

Eli Lilly and Company (NYSE: LLY) will participate in the SVB Securities Global Biopharma Conference on Thursday, Feb. 16, 2023.

Osteal Therapeutics, Inc. (“Osteal”), a clinical-stage biopharmaceutical company developing a new category of combination therapies for musculoskeletal infections, announced today the first subject enrollment in its next Phase 2 study, known as APEX-2 (Abbreviated Protocol for Two Stage Exchange).

PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the “Company” or “PreveCeutical”), is pleased to announce that on February 1, 2023, PreveCeutical has appointed ICON as the clinical research organization (CRO) to complete the following.

LevitasBio, Inc. (www.levitasbio.com), a premier end-to-end sample processing and cellular analysis provider to the life sciences market, unveils a suite of LeviSelectTM cell depletion and enrichment kits for immunology research.

Therap Services offers a Time Tracking module which is designed to document data over a specific period of time at regular intervals in order to monitor and record multiple activities of individuals.

BioCare, Inc., specializing in delivering specialty and therapeutic biological products since 1982, has named two healthcare industry veterans to their leadership team.

Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, announced today that it will release its fourth quarter and full year 2022 financial results on Monday, February 27, 2023.

Regen BioPharma, Inc. (OTC PINK: RGBP) and (OTC PINK: RGBPP), a biotechnology company advancing a diverse pre-clinical pipeline spanning cell therapies, RNA vaccines, RNA and DNA therapeutics and small molecule drugs will be presenting at the Emerging Growth Conference on February 8, 2023.